The study group received chemotherapy ( cisplatin , gemcitabine , paclitaxel , and pemetrexed ) under the guidance of molecular markers ( excision repair cross-complementing 1 ERCC1 , ribonucleotide reductase M1 RRM1 , Class III beta-tubulin , thymidylate synthetase TS ) .